Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 1492

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Prof Xavier Leleu speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about the real-world use of carfilzomib therapy among patients with existing cardiovascular medical history.

He explains that most of the clinical trials for carfilzomib have excluded patients with prior issues of cardiovascular issues leaving this population with no data.

Prof Leleu reports that this study was able to show that patients with cardiovascular issues who have been exposed to carfilzomib experienced no major issues.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Oncology knowledge

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation